Somavaratan

Generic Name
Somavaratan
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1448335-08-7
Unique Ingredient Identifier
4Y05SI704S
Background

Somavaratan has been used in trials studying the treatment of Growth Disorders and Adult Growth Hormone Deficiency.

Associated Conditions
-
Associated Therapies
-

A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2017-05-09
Last Posted Date
2018-03-09
Lead Sponsor
Versartis Inc.
Target Recruit Count
21
Registration Number
NCT03145831
Locations
🇺🇸

Eric Humphriss, Menlo Park, California, United States

Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2016-03-25
Last Posted Date
2023-04-13
Lead Sponsor
Versartis Inc.
Target Recruit Count
36
Registration Number
NCT02719990

Versartis International Trial in Adults With Long-Acting Growth Hormone

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-08-18
Last Posted Date
2022-07-26
Lead Sponsor
Versartis Inc.
Target Recruit Count
36
Registration Number
NCT02526420
Locations
🇦🇺

The Alfred Hospital, Melbourne, Victoria, Australia

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇦🇺

St Vincent's Hospital, Fitzroy, Victoria, Australia

and more 15 locations

Long-Acting Growth Hormone in Children Compared to Daily rhGH

Phase 3
Completed
Conditions
Interventions
First Posted Date
2015-01-15
Last Posted Date
2022-12-30
Lead Sponsor
Versartis Inc.
Target Recruit Count
138
Registration Number
NCT02339090

Versartis Long-Term Safety Study of Somavaratan

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2014-02-21
Last Posted Date
2018-03-09
Lead Sponsor
Versartis Inc.
Target Recruit Count
385
Registration Number
NCT02068521
© Copyright 2024. All Rights Reserved by MedPath